Ephedra is a plant-based substance from the herb Ephedra sinica. Ephedra is used in many over-the-counter weight loss products. It is also used by some athletes who believe it can improve their performance. It may be combined with herbs containing caffeine (such as guarana) or with other substances in these supplements. Ephedra, also known as ma huang, has also been used in traditional Chinese medicine to treat asthma or other lung problems. Because ephedra is marketed by companies as a supplement (not a drug to treat a disease), the US Food and Drug Administration (FDA) does not regulate its use. However, many serious adverse (bad) effects related to ephedra use have been reported. Recent research has shown that use of ephedra appears to be more risky than use of other herbal preparations.
The March 26,2003, issue of JAMA includes an article about the efficacy and safety of ephedra and ephedrine.
Ephedrine is a chemical contained in the ephedra herb. Ephedrine has medical uses, mostly in operating rooms and intensive care units. Its chemical properties raise blood pressure and heart rate and open up the large air passages in the lungs. Ephedrine is safe when used under the supervision of a doctor and with proper monitoring of the patient. Ephedrine has also been used as a weight loss product and by athletes who believe it makes them stronger or have more energy and endurance. However, this has not been proven and this type of unmonitored use for nonmedical reasons may not be safe.
ÃÂïÃÂÿÃÂýElevated blood pressure
Palpitations
Headache
Nausea
Agitation or restlessness
Psychiatric disturbances
Heart attack
Stroke
Death
Individuals with very high risks for adverse effects include children younger than 18 years; women who are pregnant or nursing; individuals who have health conditions such as high blood pressure, heart disease, eizure disorder, depression, diabetes, thyroid or liver disorders; and those who are using prescription medicines.
For anyone, the risks of bad effects from ephedra or ephedrine products far outweigh the possible minimal benefits. Products that are natural or plant-based are not necessarily safe just because they come from plants. Plants produce chemicals that can be dangerous and may interact with other medications you are taking. Discuss with your doctor any herbal or plant-based products you use.
If you believe you have experienced a harmful side effect from ephedra or ephedrine, you or your doctor should report it to the FDA. The FDA has a hotline called MEDWATCH (800/FDA-1088) for reporting problems connected with the use of supplements, drugs, or medical devices. Your identity will be kept confidential. You may also use the FDA Web site (see For More Information) to access MEDWATCH for online reporting.
US Food and Drug Administration (includes a link to MEDWATCH to report adverse events)http://www.fda.gov
National Center for Complementary and Alternative Medicinehttp://www.nccam.nih.gov
National Institutes of Health Office of Dietary Supplementshttp://dietary-supplements.info.nih.gov
To find this and previous JAMA Patient Pages, go to the Patient Page Index on JAMA's Web site at http://www.jama.com. They are available in English and Spanish.
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. Any other print or online reproduction is subject to AMA approval. To purchase bulk reprints, call 718/946-7424.
Sources: US Food and Drug Administration, US Department of Health and Human Services, National Center for Complementary and Alternative Medicine, National Institutes of Health
Topic: DIETARY SUPPLEMENTS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.